Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2364673 Target Snapshot

1,3-beta-glucan synthase · SINGLE PROTEIN · Candida

Back to Search Search this target Browse approvals Evidence Card
7Compounds
1Assays
0Approved Drugs
7.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

1,3-beta-glucan synthase shows approved-linked disease relevance led by aspergillosis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O13428. Start with aspergillosis, then reuse UniProt O13428 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with aspergillosis, then reuse UniProt O13428 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 4 linked drugs
Open source guide
Disease program
aspergillosis

1,3-beta-glucan synthase shows approved-linked disease relevance led by aspergillosis. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with aspergillosis because it currently carries approved-linked support. Linked drugs include ANIDULAFUNGIN, CASPOFUNGIN ACETATE, IBREXAFUNGERP, MICAFUNGIN SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 1,3-beta-glucan synthase as ChEMBL target CHEMBL2364673, mapped to UniProt O13428. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
1,3-beta-glucan synthase
SINGLE PROTEIN · Candida
As of 2026-09-14
ChEMBL target ID
CHEMBL2364673
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O13428
1,3-beta-glucan synthase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 1,3-beta-glucan synthase is the right protein anchor across sources, using UniProt O13428 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why aspergillosis is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name1,3-beta-glucan synthase
Target TypeSINGLE PROTEIN
OrganismCandida
UniProtO13428
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label1,3-beta-glucan synthase
UniProt AccessionO13428
Component TypeProtein
Sequence Length1897 aa

1,3-beta-glucan synthase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 1,3-beta-glucan synthase, mapped to UniProt O13428. Sequence length is 1897 aa.

Mapped IDO13428
Review name1,3-beta-glucan synthase
OrganismCandida
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

1,3-beta-glucan synthase shows approved-linked disease relevance led by aspergillosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
aspergillosis
4 linked drugs · 4 direct · 4 efficacy
Linked drugANIDULAFUNGIN
Linked drugCASPOFUNGIN ACETATE
Linked drugIBREXAFUNGERP
Linked drugMICAFUNGIN SODIUM
Approved-linked Approved
fungal infectious disease
4 linked drugs · 4 direct · 4 efficacy
Linked drugANIDULAFUNGIN
Linked drugCASPOFUNGIN ACETATE
Linked drugIBREXAFUNGERP
Linked drugMICAFUNGIN SODIUM
Approved-linked Approved
Candidemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugANIDULAFUNGIN
Linked drugCASPOFUNGIN ACETATE
Linked drugIBREXAFUNGERP
Approved-linked Approved
candidiasis
3 linked drugs · 3 direct · 3 efficacy
Linked drugANIDULAFUNGIN
Linked drugCASPOFUNGIN ACETATE
Linked drugMICAFUNGIN SODIUM
Approved-linked Approved
vulvovaginal candidiasis
2 linked drugs · 2 direct · 2 efficacy
Linked drugIBREXAFUNGERP
Linked drugIBREXAFUNGERP CITRATE
Approved-linked Approved
peritonitis
1 linked drug · 1 direct · 1 efficacy
Linked drugANIDULAFUNGIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with aspergillosis because it currently carries approved-linked support. Linked drugs include ANIDULAFUNGIN, CASPOFUNGIN ACETATE, IBREXAFUNGERP, MICAFUNGIN SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseaspergillosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC507.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3693941 5.57 IC50 2700.0 Preclinical
CHEMBL3693943 5.27 IC50 5400.0 Preclinical
CHEMBL3693942 5.1 IC50 8000.0 Preclinical
CHEMBL3693938 5.07 IC50 8500.0 Preclinical
CHEMBL3693944 4.92 IC50 12000.0 Preclinical
CHEMBL3693939 4.82 IC50 15000.0 Preclinical
CHEMBL3693940 4.47 IC50 34000.0 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
1
5.5
0
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

1
Total Assays
7
Tested Compounds
1
Assay Types
Binding — 1 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 7 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine